Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts

@inproceedings{Wei2014NovelCD,
  title={Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts},
  author={Wei Wei and Song Wu and Xiao-lin Wang and Chris Kin-Wai Sun and Xiaoyang Yang and Xinrui Yan and M Chua and Samuel K. So},
  booktitle={Oncotarget},
  year={2014}
}
The molecular co-chaperone CDC37 is over-expressed in hepatocellular carcinoma (HCC) cells, where it functions with HSP90 to regulate the activity of protein kinases in multiple oncogenic signaling pathways that contribute towards hepatocarcinogenesis. Disruption of these signaling pathways via inhibition of HSP90/CDC37 interaction is therefore a rational therapeutic approach. We evaluated the anti-tumor effects of celastrol, pristimerin, and two novel derivatives (cel-D2, and cel-D7) on HCC… CONTINUE READING